Amalgamated Bank Decreases Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Amalgamated Bank trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,628 shares of the medical equipment provider’s stock after selling 2,272 shares during the period. Amalgamated Bank’s holdings in Lantheus were worth $2,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of LNTH. Principal Securities Inc. purchased a new stake in shares of Lantheus in the 4th quarter valued at about $28,000. Janney Montgomery Scott LLC lifted its holdings in shares of Lantheus by 6.2% in the 4th quarter. Janney Montgomery Scott LLC now owns 8,005 shares of the medical equipment provider’s stock valued at $497,000 after purchasing an additional 467 shares during the last quarter. Norges Bank purchased a new stake in shares of Lantheus in the 4th quarter valued at about $29,956,000. PNC Financial Services Group Inc. lifted its holdings in shares of Lantheus by 14.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,613 shares of the medical equipment provider’s stock valued at $596,000 after purchasing an additional 1,202 shares during the last quarter. Finally, Quest Partners LLC purchased a new stake in shares of Lantheus in the 4th quarter valued at about $101,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Insiders have sold a total of 40,852 shares of company stock worth $3,922,001 in the last quarter. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH opened at $111.76 on Wednesday. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $105.14 and its two-hundred day moving average is $85.08. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The stock has a market capitalization of $7.75 billion, a price-to-earnings ratio of 17.06 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the previous year, the firm posted $1.40 EPS. The business’s revenue for the quarter was up 22.5% on a year-over-year basis. Research analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the subject of several research reports. JMP Securities reduced their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Truist Financial reduced their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Leerink Partners upped their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.